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6 months, 1.1% at 12 months, and 7% at 8 years.
Conclusions: The most common causes of syncope while driv-
ing are vasodepressor syncope and an arrhythmia, and with
appropriate therapy, the risk of recurrent syncope while
driving is approximately 1%/year.
Perspective: Patients who have had syncope while driving
generally are advised to not drive for 6-12 months.
However, noncompliance is common. Therefore, it is reas-
suring to note that the risk of recurrent syncope while
driving is very low in the first year of follow-up and there-
after, with appropriate therapy.
Summary written by: Fred Morady, MD  
Racial Differences in Survival After In-Hospital
Cardiac Arrest
Chan PS, Nichol G, Krumholz HM, et al.
JAMA 2009;302:1195–1201.
Study Design: Is survival after in-hospital cardiac arrest
(IHCA) lower in black or white patients? 
Methods: Data on 10,011 patients (mean age 66.6 years) with
IHCA at 274 hospitals were obtained from a national cardiac
arrest registry. The primary outcome was survival to hospital
discharge. Effects of patient and hospital characteristics on
survival were examined.
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Arrhythmias
Syncope While Driving: Clinical Characteristics,
Causes, and Prognosis
Sorajja D, Nesbitt GC, Hodge DO, et al.
Circulation 2009;120:928–934.
Study Design: What are the causes and clinical implications of
syncope while driving? 
Methods: This retrospective, case-control study evaluated
3,877 patients (mean age 56 years) in 1996-1998 for syn-
cope. Syncope occurred during driving in 381 patients
(9.8%). The cause was ascertained by review of medical
records, and follow-up information was obtained via a survey
mailed to patients.
Results: Compared to the 3,496 control patients with syncope
not while driving, the driving group more often had struc-
tural heart disease (26.5% vs. 21%), a prodrome of nausea
(26.8% vs. 22%), and injury (28.6% vs. 23.7%). The most
common causes of syncope in the driving group were
vasodepressor syncope (37.3%) and an arrhythmia (11.8%);
prevalence was similar in the control group. Therapy con-
sisted of counseling, medications, a pacemaker, or an
implantable cardioverter-defibrillator, as indicated. Syncope
recurred in a similar percentage of patients in the driving
and control groups (25.1% and 28.9%, respectively, at 8
years). Recurrence of syncope while driving was 0.7% at 
they are appropriate candidates for an implantable car-
dioverter-defibrillator regardless of the results. 
6: Electrophysiological testing may be useful in patients with
syncope and suspected intermittent bradycardia, atrioven-
tricular block, or paroxysmal tachycardia.  
7: First-line therapy of neurocardiogenic syncope consists of
patient education on hydration, high salt intake, avoidance
of triggers, recognition of prodromal symptoms, supine pos-
ture, isometric contraction of large muscle groups, and
avoidance of alcohol.  
8: The majority of trials have shown that beta-blockers,
disopyramide, scopolamine, midodrine, clonidine, and sero-
tonin reuptake inhibitors do not prevent neurocardiogenic
syncope.   
9: When evaluated in double-blinded fashion, pacing did not
significantly reduce the recurrence rate of neurocardiogenic
syncope.  
10: Unexplained syncope is a major risk factor for sudden
death in hypertrophic cardiomyopathy if it occurred within 6
months before evaluation.   
Summary written by: Fred Morady, MD
Dabigatran Versus Warfarin in Patients With 
Atrial Fibrillation
Connolly SJ, Ezekowitz MD, Yusuf S, et al., on behalf of the RE–LY
Steering Committee and Investigators.
N Engl J Med 2009;361:1139–1151.
Study Design: Does the direct thrombin inhibitor (DTI) dabi-
gatran prevent thromboembolic events as effectively as
warfarin in patients with atrial fibrillation (AF)?
Methods: The RE–LY study consisted of 18,113 patients
(mean age 71 years) with AF and ≥1 risk factor for stroke.
The patients were randomly assigned to receive: dabigatran
110 mg twice/day (n = 6,015), dabigatran 150 mg twice/day
(n = 6,076), or adjusted-dose warfarin to maintain an inter-
national normalized ratio (INR) of 2-3 (n = 6,022). Median
follow-up was 2 years.
Results: The annual rates of stroke/systemic embolism were
1.53% and 1.11% in the lower- and higher-dose dabigatran
groups, and 1.69% in the warfarin group. Compared to
warfarin, lower-dose dabigatran was equivalent and higher-
dose was superior. Annual rates of hemorrhagic stroke in
the lower- and higher-dose dabigatran groups (0.12% and
0.10%) were significantly lower than warfarin (0.38%).
Annual rate of major bleeding was significantly lower in the
lower-dose dabigatran group (2.71%), but not in the
higher-dose group (3.11%) compared to warfarin (3.36%).
Results: There were 8,128 white patients and 1,883 black
patients. Survival to hospital discharge was significantly
lower in black (25.2%) than white patients (37.4%). The
relative difference in survival of 27% narrowed to 19% when
the analysis was adjusted for differences in patient charac-
teristics, and further narrowed to 11% when hospital
characteristics were taken into account. Delayed defibrilla-
tion was more common for blacks (22%) than whites
(17.4%). Among 6,529 patients who survived the initial
IHCA, survival to hospital discharge was lower for blacks
(45.2%) than whites (55.5%), attributable mostly to hospital
site where post-resuscitation care was delivered.
Conclusions: Compared to white patients, black patients are
less likely to survive after IHCA.
Perspective: Since much of the racial disparity in survival after
IHCA was attributable to differences in hospital factors,
standardization of hospital personnel and protocols for
responding to IHCA could minimize the racial disparity.
Whether unmeasured factors such as clinician or hospital
bias also contribute to racial disparity in survival is unclear.
Summary written by: Fred Morady, MD 
Guidelines for the Diagnosis and Management of
Syncope (Version 2009): The Task Force for the
Diagnosis and Management of Syncope of the
European Society of Cardiology (ESC)
Moya A, Sutton R, Ammirati F, et al.
Eur Heart J 2009;Aug 27:[Epub ahead of print].
Perspective: The following are 10 points to remember from
these syncope guidelines, developed by the European Society
of Cardiology:
1: The two most common causes of syncope are neurocar-
diogenic syncope and cardiac disorders, which account for
>50% of syncopal episodes.
2: The initial evaluation of patients >40 years should include
sequential right and left carotid sinus massage for 10 sec-
onds; asystole >3 seconds with reproduction of symptoms is
indicative of carotid sinus syndrome.
3: The main indication for tilt testing is to confirm neuro-
cardiogenic syncope when suspected. Tilt testing is of no
value for assessing response to therapy.
4: Implantable loop recorders may be more cost-efficient
than conventional monitoring or external loop recorders for
diagnosing patients with sporadic syncope. 
5: Electrophysiological testing is unnecessary in patients
with syncope and an ejection fraction <30-35%, because




ature. It is well proven that statin use reduces cardiovascular
events in patients at risk. The current study demonstrates
rather significantly that this appears to be true for periopera-
tive cardiovascular events in patients undergoing major
vascular surgery.  
Summary written by: James B. Froehlich, MD    
Effects of Initiating Insulin and Metformin on
Glycemic Control and Inflammatory Biomarkers
Among Patients With Type 2 Diabetes: The LANCET
Randomized Trial 
Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM.
JAMA 2009;302:1186–1194. 
Study Question: What is the effect of insulin alone or com-
bined with metformin in lowering levels of high-sensitivity
C-reactive protein (hs-CRP), interleukin-6 (IL-6), and sol-
uble tumor necrosis factor receptor 2 (sTNFr2) in patients
with recent-onset type 2 diabetes mellitus?
Methods: This was a randomized, 2 x 2 factorial trial of
open-label insulin glargine and placebo-controlled met-
formin in 500 adults with type 2 diabetes, suboptimal
glycemic control, and elevated hs-CRP levels. Patients were
randomly allocated to one of four treatments (placebo met-
formin only, placebo metformin and insulin glargine, active
metformin only, or active metformin and insulin glargine)
with dose titration targeting fasting blood glucose <110
mg/dl. The primary outcome measure was change in hs-
CRP level and change in IL-6 and sTNFr2 levels from
baseline to 14 weeks. 
Results: Levels of glucose and glycated hemoglobin (HbA1c)
were significantly reduced with active treatment versus
placebo. Levels of hs-CRP were reduced in all groups. There
was no significant difference in hs-CRP reduction among
those allocated to insulin or to no insulin, or among those
allocated to active metformin or placebo metformin. In the
individual treatment groups, despite a differential impact on
glucose control, reductions in hs-CRP in the metformin and
metformin plus insulin groups were no different than reduc-
tions with placebo alone. By contrast, hs-CRP reduction was
attenuated with insulin alone. Similar findings were noted for
levels of IL-6 and sTNFr2.
Conclusions: In patients with recent-onset type 2 diabetes,
treatment with insulin or metformin compared with placebo
did not reduce inflammatory biomarker levels despite
improving glucose control.
Perspective: These data provide important insights into the
complex interrelationships that underlie inflammation and
atherosclerosis in diabetic patients. These data emphasize
Conclusions: Depending on the dose, dabigatran is either
equivalent or superior to warfarin for preventing throm-
boembolic events in patients with AF, and is associated with
an equivalent or lower risk of major bleeding.
Perspective: DTIs are an attractive alternative to warfarin
because INR monitoring and dose adjustment are not
required, and they provide a steadier anticoagulation effect
between dosages. Another DTI, ximelagatran, was shown to
be equal to warfarin for preventing strokes, but did not gain
market approval because of hepatotoxicity. A major advantage
of dabigatran is that it does not appear to be hepatotoxic. 
Summary written by: Fred Morady, MD
General Cardiology
Fluvastatin and Perioperative Events in Patients
Undergoing Vascular Surgery
Schouten O, Boersma E, Hoeks SE, et al.
N Engl J Med 2009;361:980–989. 
Study Question: Does perioperative statin therapy improve
postoperative incidence of adverse cardiac events in patients
undergoing vascular surgery?
Methods: The authors reported the results of DECREASE
III, a randomized, blinded, placebo-controlled trial of fluva-
statin 80 mg daily versus placebo, started prior to surgery
(median 37 days), in subjects >age 40 undergoing major aor-
tic, peripheral vascular bypass, or carotid endarterectomy
surgery. The primary endpoint was myocardial ischemia
within 30 days of surgery. Secondary endpoint was death
from cardiovascular causes or myocardial infarction (MI).
Also, lipids, interleukin-6, and C-reactive protein levels were
measured at the time of randomization and before surgery. 
Results: Among 497 subjects, 250 received fluvastatin, and 247
received placebo. By the time of surgery, low-density lipopro-
tein, total cholesterol, interleukin-6, and C-reactive protein
were all significantly lower in the treatment group, but
unchanged in the placebo group. Myocardial ischemia was
much less frequent in the fluvastatin versus placebo groups
(27 vs. 47, respectively; p = 0.01). Death from cardiovascular
causes or MI was also less frequent in the fluvastatin versus
placebo groups (12 vs. 25, respectively; p = 0.03).
Conclusions: Among patients undergoing vascular surgery,
perioperative fluvastatin therapy was associated with an
improvement in postoperative cardiac outcome.
Perspective: Several small studies previously suggested that
perioperative statin use improves cardiovascular adverse
events. This study adds significantly more weight to that liter-
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the need to encourage therapies that do reduce cardiovascu-
lar events among diabetic patients, including regular
exercise, weight management, smoking cessation, optimal
blood pressure control, and in appropriate patients,
antiplatelet and lipid-lowering therapies.  
Summary written by: Debabrata Mukherjee, MD     
Should We Be Applying Warfarin Pharmacogenetics
to Clinical Practice? No, Not Now
Rosove MH, Grody WW.
Ann Intern Med 2009;151:270–273.
Perspective: The following are 10 points to remember about
applying warfarin pharmacogenetics to clinical practice.
1: To date, randomized clinical trials have failed to demon-
strate any benefit associated with the use of genetic testing
when initiating warfarin therapy. Current guidelines from
the American College of Chest Physicians suggest against
the use of pharmacogenetic-based dosing.
2: Warfarin is metabolized by the cytochrome P450 system.
Two single nucleotide polymorphisms in the responsible
gene, CYP2C9*2 and *3, lead to slower metabolism of the
active form of warfarin. They have been associated with the
need for significantly lower doses of warfarin to achieve
therapeutic international normalized ratio (INR).
3: Warfarin targets the function of the enzyme vitamin K
epoxide reductase. Several single nucleotide polymorphisms
in the gene for this enzyme have been identified, which alter
its sensitivity to warfarin, resulting in both increased and
decreased warfarin sensitivity. The presence of these muta-
tions has been associated with significantly altered doses of
warfarin to achieve therapeutic INR.
4: Commercial pharmacogenetic tests have become available
to identify these genetic mutations. 
5: In 2007, the US Food and Drug Administration inserted
wording into the package insert for warfarin, suggesting the
use of pharmacogenetic testing. 
6: A recent study estimating the impact of pharmacogenetic
testing on warfarin dosing suggested that genotype informa-
tion was of no benefit in predicting warfarin dose among
the majority of patients. Although the benefit was slightly
greater in those requiring unusually high doses, it applied to
less than one quarter of patients.  
7: Randomized trials of genotype-based warfarin dosing ver-
sus standard, currently used algorithms have demonstrated
no difference in the speed with which target INR is
achieved, or the frequency of out-of-range INR.  
8: A cost-effectiveness study suggested that, at current test
pricing, genetic analysis was not at all cost-effective, with an
estimated cost of more than $170,000 per quality-adjusted
life-year.   
9: To use genetic testing clinically, a rapid-response molecu-
lar genetic testing capability would need to be in place for
clinicians to receive genetic analysis results on the same day
as initiating warfarin therapy. The low cost-effectiveness of
genetic testing did not consider the additional cost of estab-
lishing this infrastructure.  
10: The National Heart, Lung, and Blood Institute is spon-
soring a randomized clinical trial to test pharmacogenomic
dosing versus standard dosing in the initiation of warfarin
therapy.   
Summary written by: James B. Froehlich, MD
Usual Versus Tight Control of Systolic Blood
Pressure in Non-Diabetic Patients With
Hypertension (Cardio-Sis): An Open-Label
Randomised Trial
Verdecchia P, Staessen JA, Angeli F, et al., on behalf of the Cardio-Sis
Investigators.
Lancet 2009;374:525–533.
Study Question: Is tight control (<130 mm Hg) compared
with usual control (<140 mm Hg) of systolic blood pressure
beneficial in nondiabetic patients with hypertension?
Methods: This was an open-label trial in 44 centers in Italy,
which randomized subjects having a systolic blood pressure
≥150 mm Hg to either a target systolic blood pressure of <140
mm Hg (usual control) versus <130 mm Hg (tight control).
The primary endpoint was electrocardiographic (ECG) evi-
dence of left ventricular hypertrophy (LVH) 2 years after
randomization, based on intention to treat. Prespecified sec-
ondary endpoint was a composite of all-cause mortality, fatal
or nonfatal MI, fatal or nonfatal stroke, congestive heart fail-
ure requiring admission, angina with objective evidence of
ischemia, atrial fibrillation, coronary revascularization, aortic
dissection, peripheral arterial disease, and renal failure requir-
ing dialysis.
Results: After a median follow-up of 2.0 years, both systolic
and diastolic blood pressure were reduced by a mean of
27.3/10.4 mm Hg in the tight control group (n = 558), and
a mean of 23.5/8.9 mm Hg in the usual control group (n =
553). Fewer subjects developed LVH by ECG in the tight
control group versus usual control (11.4% vs. 17.0%, respec-
tively; p = 0.13). The secondary endpoint occurred in 4.8%
of subjects in the tight control versus 9.4% in the usual con-
trol group (p = 0.003). 




reduction in ischemic events and a safety profile similar to
that of UFH plus eptifibatide.
Perspective: Intermediate doses of otamixaban were clearly
associated with a reduction in ischemic events compared
with eptifibatide, although bleeding rates were all higher
with intermediate and high doses of otamixaban. It appears
that the anti-ischemic efficacy of otamixaban comes at the
cost of increased bleeding; thus, this drug is unlikely to
emerge as pre-eminent for patients with NSTE-ACS.  
Summary written by: Hitinder S. Gurm, MD    
Guidelines on the Prevention, Diagnosis, and
Treatment of Infective Endocarditis (new version
2009): The Task Force on the Prevention,
Diagnosis, and Treatment of Infective Endocarditis
of the European Society of Cardiology (ESC)
Habib G, Hoen B, Tornos P, et al.
Eur Heart J 2009;Aug 27:[Epub ahead of print].
Perspective: This is a summary statement issued by the
European Society of Cardiology (ESC) addressing the pre-
vention, diagnosis, and treatment of infective endocarditis
(IE). Points to remember are:
1: Rationale: As justification for issuing new guidelines, the
ESC committee cites evolution in the nature of IE, and
recent publication of new guidelines or state-of-the-art
papers addressing the same topic.
2: Epidemiology: The epidemiology of IE has changed, now
more often affecting elderly patients and occurring as a result
of health care–associated procedures. IE can be categorized as
left-sided native valve IE, left-sided prosthetic valve IE,
right-sided IE, or device-related IE.
3: Pathophysiology: Because normal vascular endothelium is
relatively resistant to infection, IE typically involves the
combination of mechanical disruption of the endothelium,
transient bacteremia, and interaction between the microbio-
logical pathogen and host defenses.
4: Preventative measures: Similar to other recent guidelines
and statements, the committee recommends a dramatic
change in the indications for use of prophylactic antibiotics
to prevent IE, limiting prophylaxis only to patients with
“the highest risk of IE undergoing the highest risk proce-
dures.” Unlike the ACC/AHA guidelines, patients with
heart valve disease after heart transplant are not included. 
5: Diagnosis: IE can present with a variety of clinical scenarios.
Transthoracic echocardiography should be used as a first-line
imaging modality. At least three blood cultures should be
Conclusions: These findings lend support to a lower blood
pressure goal than is recommended in nondiabetic patients
with hypertension.
Perspective: This important and well-designed study accom-
plishes what is rarely performed: a randomized trial of
different therapeutic targets. These data conclude that antihy-
pertensive therapy with a target of 130 mm Hg systolic blood
pressure is superior to a target of 140 mm Hg systolic. These
data also provide important clinical trial evidence that a treat-
ment goal of lower blood pressure may reduce clinical events,
without any difference in side effects. Further study of lower
target blood pressure treatment is ongoing.  
Summary written by: James B. Froehlich, MD 
Otamixaban for the Treatment of Patients With
Non–ST-Elevation Acute Coronary Syndromes
(SEPIA-ACS1 TIMI 42): A Randomised, Double-
Blind, Active-Controlled, Phase 2 Trial
Sabatine MS, Antman EM, Widimsky P, et al.
Lancet 2009;374:787–795.
Study Question: What is the safety and efficacy of otamixaban,
an intravenous direct factor Xa inhibitor in the treatment of
patients with non–ST-elevation acute coronary syndrome
(NSTE-ACS)?
Methods: Trial investigators randomized 3,241 patients with
NSTE-ACS to one of five doses of otamixaban (0.08 mg/kg
bolus followed by infusions of 0.035 [n = 125], 0.070 [n =
676], 0.105 [n = 662], 0.140 [n = 658], or 0.175 [n = 671]
mg/kg/h) or a control group (n = 449) who were treated
with unfractionated heparin (UFH; 60 IU/kg intravenous
bolus followed by an infusion of 12 IU/kg/h) plus eptifi-
batide. The primary efficacy endpoint was a composite of
death, myocardial infarction, urgent revascularization, or
bailout glycoprotein IIb/IIIa inhibitor use up to 7 days. The
primary safety endpoint was TIMI major or minor bleeding
not related to coronary artery bypass grafting. 
Results: Enrollment into the lowest dose group of otamixaban
was stopped early due to increased risk of thrombotic compli-
cations. Among the otamixaban group, the primary efficacy
endpoint occurred in 7.2% of patients with 0.035 mg/kg/h,
4.6% with 0.070 mg/kg/h, 3.8% with 0.105 mg/kg/h, 3.6%
with 0.140 mg/kg/h, and 4.3% with 0.175 mg/kg/h. Among
patients treated with UFH and eptifibatide, the rate was
6.2%. TIMI major or minor bleeding occurred in 2.7% of the
control group compared with 1.6%, 1.6%, 3.1%, 3.4%, and
5.4%, respectively, with the five otamixaban doses.
Conclusions: In patients with NSTE-ACS, otamixaban infu-
sions of 0.100-0.140 mg/kg/h were associated with a
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drawn for diagnosis, with at least one for both aerobic and
anaerobic culture. The modified Duke criteria are recom-
mended for IE diagnosis. 
6: Prognosis: Adverse prognosis associated with IE is predicted
by patient characteristics, complications of IE, microorganism,
and echocardiography findings.  
7: Antimicrobial therapy: Specific recommendations are given
for oral Streptococci or group B Streptococci IE, Staphylococcus
IE, Enterococcus IE, and for blood culture-negative IE.
Prosthetic valve IE should be treated for 6 weeks; native
valve IE for 2-6 weeks.  
8: Indications for surgery: Surgery for left-sided native valve
IE is indicated emergently or urgently for depending on the
type of heart failure, and electively for regurgitation without
heart failure.   
9: Complications: Other clinical occurrences can complicate
the course of IE. After a silent cerebral embolism or tran-
sient ischemic attack, surgery is recommended without delay
if an indication remains. Following intracranial hemorrhage,
surgery must be delayed for at least 1 month. Neurosurgery
or endovascular therapy is indicated for very large, enlarging,
or ruptured intracranial aneurysm.  
10: Specific other situations: The task force makes recommen-
dations for other conditions, including prosthetic valve IE, IE
involving pacemaker or defibrillator leads, right-sided IE, IE
occurring in patients with congenital heart disease, IE in eld-
erly patients, and IE during pregnancy.
Summary written by: David S. Bach, MD  
The Net Clinical Benefit of Warfarin Anticoagulation
in Atrial Fibrillation
Singer DE, Chang Y, Fang MC, et al.
Ann Intern Med 2009;151:297 –305.
Study Question: What is the net clinical benefit (considering
thromboembolic and hemorrhagic risk) of warfarin therapy
in patients with atrial fibrillation (AF)?
Methods: This was a cohort study of patients with AF in the
Kaiser Permanente System between 1996 and 2003. Data
gathered included patient characteristics, CHADS2 score,
warfarin exposure, and outcomes. Net benefit was defined as
the annual rate of thromboemboli prevented by warfarin,
minus intracranial hemorrhages (ICHs) attributable to war-
farin, multiplied by an impact weight. The base-case impact
weight was 1.5, reflecting the greater clinical impact of ICH
versus thromboembolism.
Results: Among 13,599 subjects, there were 66,000 person-
years of follow-up. The adjusted net clinical benefit of
warfarin for the cohort overall was 0.68% per year, and was
greater for those with a history of stroke (2.48% per year) and
those 85 years of age and older (2.34% per year). The net
clinical benefit was negligible for those with a CHADS2
score of 0 or 1, and roughly 1% per year for those with a
CHADS2 score of 2 (0.97% per year). For subjects with a
CHADS2 score of 4-6, the net clinical benefit was 2.22% per
year. These findings were unchanged by sensitivity analyses
performed by adjusting the weighting factor for ICH.
Conclusions: The expected net clinical benefit from warfarin
was highest in patients with AF who have the highest risk for
stroke, including those in the oldest age category. A risk
assessment incorporating both risk of ICH and thromboem-
bolism provided the most quantitatively informed basis for the
decision to anticoagulate patients with AF.
Perspective: Importantly, this study emphasizes that ability to
prevent stroke is not the only measure of the effect of war-
farin—one must also factor in the increased risk of ICH
caused by warfarin. Only the net of these risks and benefits is
useful in deciding to prescribe warfarin. It may come as a sur-
prise that patients over age 85 benefit significantly more than
younger patients from warfarin therapy, even when ICH risk
is taken into account.  
Summary written by: James B. Froehlich, MD 
Improved Oral Anticoagulation After a Dietary
Vitamin K–Guided Strategy: A Randomized
Controlled Trial
de Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE.
Circulation 2009;120:1115–1122.
Study Question: Will a strategy of modifying dietary vitamin K
intake improve management of oral warfarin therapy com-
pared with a conventional dosage adjustment strategy?
Methods: This randomized trial compared conventional dosage
adjustment management of warfarin therapy, versus a dietary
vitamin K strategy. Subjects on warfarin therapy greater than
3 months, and with an international normalized ratio (INR)
out of target range, were invited to participate. Those with
active bleeding or thrombosis were excluded. After assess-
ment of baseline vitamin K intake, subjects in the dietary
group were instructed to double or halve their vitamin K
intake if their INR was high or low, respectively. This assess-
ment was repeated with the next INR. No adjustment of
warfarin dose was made in the dietary therapy group, unless
they experienced three consecutive out-of-range INRs.
Results: Of 132 subjects randomized, the majority had either a
mechanical heart valve (58%) or atrial fibrillation (35%), with
similar frequency in each group. Magnitude and direction of




INR variation was comparable in the two groups. The vitamin
K-directed therapy group achieved target INR more rapidly,
being in target range at 90-day follow-up in 75% versus 58%
of cases in the dosage-adjustment group (p = 0.04). This trend
continued at 15-, 30-, and 60-day follow-up. There was also a
trend toward less bleeding and use of parenteral vitamin K in
the dietary therapy group (1 vs. 7; p = 0.06).
Conclusions: A vitamin K-guided strategy to adjust long-term
anticoagulation therapy is safe and feasible, and may result in
an improved chance of reaching target INR.
Perspective: Because vitamin K intake counteracts the effect of
warfarin, dietary variation in vitamin K intake may lead to
much of the INR variation seen clinically. Since we know the
vitamin K content of many foods, it may make more sense to
adjust patients’ vitamin K intake rather than their warfarin
intake. The current study suggests this may be very effective. I
suspect this strategy would be well received by patients, and
warrants further study.  
Summary written by: James B. Froehlich, MD  
Heart Failure/Transplant
B-CONVINCED: Beta-blocker CONtinuation vs.
INterruption in Patients With Congestive Heart
Failure HospitalizED for a Decompensation Episode
Jondeau G, Neuder Y, Eicher JC, et al., on behalf of the B-CONVINCED
Investigators.
Eur Heart J 2009;30:2186–2192.
Study Question: Should beta-blockers be stopped during acutely
decompensated heart failure (ADHF)?
Methods: The study investigators compared beta-blockade con-
tinuation versus discontinuation during ADHF in patients
with left ventricular ejection fraction below 40%, who were
previously receiving stable beta-blocker therapy. A total of 169
patients were included; 147 were evaluated.
Results: After 3 days, 92.8% of patients continuing beta-
blocker therapy improved for both dyspnea and general
well-being, versus 92.3% of patients stopping beta-blocker.
This was the main endpoint, and the upper limit for unilateral
95% confidence interval (6.6%) was lower than that of the pre-
defined upper limit (12.5%), indicating noninferiority. There
were similar findings at 8 days and when evaluation was made
by the patient. Plasma B-type natriuretic peptide at day 3,
length of hospital stay, rehospitalization rate, and death rate
after 3 months were also similar. Beta-blocker therapy at 3
months was given to 90% of patients versus 76% (p < 0.05).
Conclusions: During ADHF, continuation of beta-blocker
therapy was not associated with delayed or lesser improve-
ment, but with a higher rate of chronic prescription of
beta-blocker therapy after 3 months, the benefit of which is
well established.
Perspective: An important message from this study is that it
is not harmful to continue beta-blocker therapy, and the
benefit of continuing therapy is that more patients are likely
to receive beta-blockers long-term. In our practice, we only
stop beta-blockers in ADHF if dobutamine is started or
alternatively, milrinone may be used as an inotrope if the cli-
nician chooses to continue beta-blockers.  
Summary written by: Ragavendra R. Baliga, MBBS 
Albuminuria in Chronic Heart Failure: Prevalence
and Prognostic Importance
Jackson CD, Solomon SD, Gerstein HC, et al., on behalf of the CHARM
Investigators and Committees.
Lancet 2009;374:543–550.
Study Question: What is the prevalence and prognostic value of
a spot urinary albumin to creatinine ratio (UACR) in patients
with heart failure (HF)?
Methods: UACR was measured at baseline and during fol-
low-up of 2,310 patients in the CHARM Programme. They
assessed the prevalence of micro- and macroalbuminuria,
and the predictive value of UACR for the primary composite
outcome of each CHARM study—i.e., mortality from car-
diovascular causes or admission to hospital with worsening
HF—and mortality from any cause.
Results: Investigators found that 58% (n = 1,349) of patients
had a normal UACR, 30% (n = 704) had microalbuminuria,
and 11% (n = 257) had macroalbuminuria. Patients with an
increased UACR were older, had more cardiovascular
comorbidity, worse renal function, and higher prevalence of
diabetes than those with normoalbuminuria. However, they
noted a high prevalence of increased UACR among patients
without diabetes, hypertension, or renal dysfunction.
Elevated UACR was associated with increased risk of the
composite outcome and mortality. Therapy with candesartan
did not reduce or prevent the development of excessive
excretion of urinary albumin.
Conclusions: Increased UACR is a powerful and independent
predictor of prognosis in HF.
Perspective: The findings of this study are important, but more
data are required to determine whether UACR adds incre-
mental value to the Aaronson HF Survival Score or the Seattle
Heart Failure Model, or other biomarkers such as B-type
natriuretic peptide or tissue Doppler parameters such as E:E’.  
Summary written by: Fred Morady, MD
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Cardiac-Resynchronization Therapy for the
Prevention of Heart-Failure Events
Moss AJ, Hall WJ, Cannom DS, et al., on behalf of the MADIT-CRT Trial
Investigators.
N Engl J Med 2009;Sep 1:[Epub ahead of print].
Study Question: Does cardiac resynchronization therapy (CRT)
improve outcomes in patients with New York Heart
Association (NYHA) class I-II heart failure (HF) symptoms,
poor left ventricular function, and a bundle branch block?
Methods: Patients with NYHA class I-II HF symptoms, an
ejection fraction (EF) ≤30% (mean 24%), and QRS duration
≥130 ms were randomly assigned to undergo implantation of
an implantable cardioverter-defibrillator (ICD) with CRT (n
= 1,089) or without CRT (n = 731). The primary endpoint
was death from any cause or a nonfatal HF event (HFE). 
Results: The primary endpoint occurred significantly less often
in the CRT-ICD group (17.2%) than the ICD group
(25.3%). The mortality rate was approximately 3% in both
groups, but there was a 42% reduction in the risk of HFEs in
the CRT-ICD group. Within the CRT-ICD group, there
was a 52% reduction in HFEs in patients with a QRS ≥150
ms, but no reduction in HFEs when the QRS was <150 ms.
EF and left ventricular volumes improved to a greater degree
in the CRT-ICD group than in the ICD group. 
Conclusions: In patients with a low EF, bundle branch block,
and relatively mild HF symptoms, the CRT with an ICD
attenuates the progression of HF and has favorable effects
on left ventricular remodeling.
Perspective: Current guidelines recommend CRT only for
patients with class III-IV HF. Based on this study, it would
seem appropriate to expand the indications for CRT to
include class I-II patients with an EF ≤30% and QRS dura-
tion ≥150 ms.  
Summary written by: Fred Morady, MD 
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Effects of a Mediterranean-Style Diet on the Need
for Antihyperglycemic Drug Therapy in Patients
With Newly Diagnosed Type 2 Diabetes: A
Randomized Trial
Esposito K, Maiorino MI, Ciotola M, et al.
Ann Intern Med 2009;152:306–314.
Study Question: Does a Mediterranean-style diet reduce the
need for antihyperglycemic drugs among patients with
newly diagnosed diabetes?
Methods: This randomized controlled trial of 215 patients
compared a low-fat, calorie-restricted diet to a low-carbo-
hydrate Mediterranean-style diet. Patients needed to meet
the following criteria: body mass index >25 mg/kg2, age
30-75 years, glycated hemoglobin (HbA1c) under 11%, and
newly diagnosed type 2 diabetes who had not received anti-
hyperglycemic drugs. Exclusion criteria included
participation in a weight reduction program in the prior 6
months, less than 1 hour of regular physical activity, preg-
nancy or breastfeeding, and/or abnormal laboratory results.
The primary outcome was initiation of antihyperglycemic
medications as indicated for a follow-up HbA1c >7%. Labs
were checked at baseline and every 3 months. 
Results: After a mean follow-up of 4 years, patients in the
low-carbohydrate group were less likely to require antihy-
perglycemic drug therapy, as compared to those in the
low-fat diet group (44% vs. 70%, hazard ratio [HR], 0.63;
95% confidence interval [CI], 0.51-0.86). After adjust-
ment for changes in weight, the benefit of a
low-carbohydrate diet was slightly attenuated (HR, 0.70;
95% CI, 0.59-0.90), but still significant. Subjects in the
low-carbohydrate Mediterranean diet group also experi-
enced greater weight loss, and greater improvements in
glycemic control and coronary risk factors compared to
those in the low-fat diet group.
Conclusions: A low-carbohydrate, Mediterranean-style diet led
to favorable changes in glycemic control, which delayed the
need for antihyperglycemic drug therapy among patients
with newly diagnosed type 2 diabetes.
Perspective: These findings provide further evidence that
diet and lifestyle can significantly impact diabetes.
Providers who strongly advocate for lifestyle changes may
assist their diabetic patients in delaying or reducing the
need for pharmacologic interventions. Furthermore, these
data, although in a small sample size, suggest that a diet
with carbohydrates from whole grains and high in fiber
may be beneficial to these patients.  
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